Evidence map›Paper›PMID 38717942›Full record

ArticleThe Journal of clinical endocrinology and metabolism2024

Cardiovascular Safety and Romosozumab-The Plot Thickens.

Joshua N Farr

Abstract readEditorialComment
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Misaligned cardiovascular safety warnings for romosozumab in Japan.Journal of bone and mineral metabolism · 2025
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Joshua N FarrDivision of Endocrinology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester MN, 55905, USA.ORCID 0000-0002-3179-6414

Funding

Targeting Cellular Senescence and RAGE in Type 2 DiabetesR01DK128552 · NIDDK · UNIVERSITY OF ARIZONA · PI FARR, JOSHUA NICHOLAS · 2021 to 2025
$2.0M
Targeting cellular senescence with senolytics to improve skeletal health in older humansR21AG065868 · NIA · MAYO CLINIC ROCHESTER · PI FARR, JOSHUA NICHOLAS, KHOSLA, SUNDEEP · 2020 to 2021
$419k
NIA NIH HHS R21 AG065868NIDDK NIH HHS R01 DK128552NIH HHSNIH HHS R01 DK128552
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38717942
PMCPMC11651692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.